

REMARKS

The Office Action has been carefully reviewed. No claim is allowed. Claims 17, 19, 29, 30 and 34-39 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully solicited.

Claims 17-19, 29, 30 and 34-39 have been rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. The examiner states that one of skill in the art would have reasonably concluded that the combination of interferon and any of As₂O₃ or zVAD or DEVD would not be synergistic for inducing cell death in any type of leukemia beyond that of APL, or lymphoma. This rejection is obviated by the amendments to claims 19 and 34, without prejudice, to recite "acute promyelocytic leukemia" in place of "leukemia" or lymphoma".

In view of the above, the claims comply with 35 U.S.C. §112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By /ACY/
Allen C. Yun
Registration No. 37,971

ACY:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\S\Ser1\Koken1\Fto\2007-07-18amd_after_final.doc